Recent obesity management guidelines have recommended multiple pharmacotherapy options, depending on individual risk factors, including orlistat, GLP-1 analogues [liraglutide or semaglutide or tirzepatide], naltrexone-bupropion, phentiramine-topiramate, setmelanotide, and metreleptin (42). This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.